Alzinova: Encouraging results from Diagnostics study - Redeye

Redeye comments on Alzinova's announcement that it has completed its research collaboration with Amsterdam UMC within the company's blood-based Alzheimer's diagnostic program. The study confirmed measurable antibody signals against toxic amyloid-β oligomers in human serum, and lower reactivity in Alzheimer's patients than in age-matched controls. We view the outcome as encouraging as it confirms earlier observations in an independent sample set and meets the condition set out in the Letter of Intent with Fujirebio.

Länk till analysen i sin helhet: https://www.redeye.se/research/1186458/alzinova-encouraging-results-from-diagnostics-study?utm_source=finwire&utm_medium=RSS